Navigation Links
Patients suffering ED happy with Vardenafil drugs

BOSTON - The Journal of Sexual Medicine has published the findings of the head to head trial of PDE5 inhibitors, for treatment in patients with erectile dysfunction (ED). The study was an effort in drawing a methodical comparison of vardenafil // and sildenafil treatment in men with ED and diabetes, hypertension, and/or hyperlipidemia. The results showed that vardenafil was more efficient and patients showed preference for the use of this drug.

A total of 1,057 men participated in the study, which involved treatment using each drug for four weeks, with a one-week washout period in between. Patients were asked: 'Overall, which medication do you prefer?' along with 11 other preference questions relating to their ED treatment. Additional efficacy assessments using established scales were also used in analysis.

Data showed that 38.9% preferred vardenafil compared to 34.5% sildenafil (26.6% had no preference). Vardenafil was significantly superior to sildenafil in terms of erectile function, intercourse satisfaction and overall satisfaction. There were also a significant higher percentage of positive responses for vardenafil with regards to erection hardness for penetration, maintenance of erection, maintenance until completion, and erection confidence.

'This study represents an important step forward in our understanding of the clinical differences between PDE5 inhibitors, confirming the efficacy of vardenafil for men with erectile dysfunction,' explains Irwin Goldstein, study co-author and Editor-in-Chief of The Journal of Sexual Medicine.

There are currently three PDE5 inhibitors available to treat ED: sildenafil, tadalafil and vardenafil, all of which have previously demonstrated efficacy and tolerability in a range of patient populations, according to researchers.

Data from head-to-head clinical trials, like this one, are scarce. However, results from studies such as this should help clinicians to differentiat e among sildenafil, vardenafil, and tadalafil and to select the most appropriate for individual patients.


Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:

(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: